Siemens Healthineers Dirección

Dirección controles de criterios 4/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Bernd Montag

Chief Executive Officer (CEO)

€5.7m

Compensación total

Porcentaje del salario del CEO	24.1%
Permanencia del CEO	9.8yrs
Participación del CEO	n/a
Permanencia media de la dirección	3.8yrs
Promedio de permanencia en la Junta Directiva	4.2yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Bernd Montag en comparación con los beneficios de Siemens Healthineers?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	€2b
Jun 30 2024	n/a	n/a	€2b
Mar 31 2024	n/a	n/a	€2b
Dec 31 2023	n/a	n/a	€2b
Sep 30 2023	€6m	€1m	€2b
Jun 30 2023	n/a	n/a	€2b
Mar 31 2023	n/a	n/a	€2b
Dec 31 2022	n/a	n/a	€2b
Sep 30 2022	€6m	€1m	€2b
Jun 30 2022	n/a	n/a	€2b
Mar 31 2022	n/a	n/a	€2b
Dec 31 2021	n/a	n/a	€2b
Sep 30 2021	€5m	€1m	€2b
Jun 30 2021	n/a	n/a	€2b
Mar 31 2021	n/a	n/a	€2b
Dec 31 2020	n/a	n/a	€2b
Sep 30 2020	€4m	€1m	€1b
Jun 30 2020	n/a	n/a	€1b
Mar 31 2020	n/a	n/a	€2b
Dec 31 2019	n/a	n/a	€2b
Sep 30 2019	€4m	€1m	€2b
Jun 30 2019	n/a	n/a	€1b
Mar 31 2019	n/a	n/a	€1b
Dec 31 2018	n/a	n/a	€1b
Sep 30 2018	€3m	€613k	€1b

Compensación vs. Mercado: La compensación total ($USD6.02M) de Bernd está en línea con el promedio de empresas de tamaño similar en el mercado UK ($USD5.70M).

Compensación vs. Ingresos: La compensación de Bernd ha sido consistente con los resultados de la empresa en el último año.

CEO

Bernd Montag (55 yo)

9.8yrs

Permanencia

€5,717,000

Compensación

Dr. Bernhard Montag, also known as Bernd, serves as President and at Chairman of Management Board at Siemens Healthineers AG. He has been Chief Executive Officer at Siemens Healthineers AG since 2015 and s...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Bernhard Montag	President	9.8yrs	€5.72m	sin datos
Jochen Schmitz	CFO & Member of Management Board	6.9yrs	€2.94m	sin datos
Darleen Caron	Chief Human Resources Officer	3.8yrs	€2.56m	sin datos
Elisabeth Staudinger-Leibrecht	Member of Management Board	2.9yrs	€2.47m	sin datos
Marc Koebernick	Head of Investor Relations	no data	sin datos	sin datos
Christian Klaussner	Executive Vice President of Finance	no data	sin datos	sin datos
Andre Hartung	Head of Imaging	3.8yrs	sin datos	sin datos
Carsten Bertram	Head of Advanced Therapies	3.8yrs	sin datos	sin datos
David Pacitti	Head of Americas	3.8yrs	sin datos	sin datos
Sharon Bracken	Head of Diagnostics	2.5yrs	sin datos	sin datos
Jerry Wang	Head of China	2.8yrs	sin datos	sin datos
Vy Tran	Head of Asia Pacific Japan	2.8yrs	sin datos	sin datos

3.8yrs

Permanencia media

55yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0PMJ se considera experimentado (3.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Peer Schatz	Independent Member of Supervisory Board	3.7yrs	€229.67k	sin datos
Dow Wilson	Independent Member of Supervisory Board	1.8yrs	€133.08k	sin datos
Karl-Heinz Streibich	Independent Deputy Chairman of Supervisory Board	6.7yrs	€238.75k	sin datos
Ralf Peter Thomas	Chairman of Supervisory Board	6.7yrs	sin datos	sin datos
Marion Helmes	Independent Member of Supervisory Board	6.7yrs	€248.83k	sin datos
Roland Busch	Member of Supervisory Board	4.8yrs	sin datos	sin datos
Sarena Lin	Independent Member of Supervisory Board	1.8yrs	€118.83k	sin datos
Nathalie von Siemens	Independent Member of Supervisory Board	6.7yrs	€161.75k	sin datos
Veronika Bienert	Member of Supervisory Board	1.8yrs	€132.33k	sin datos
Peter Korte	Member of Supervisory Board	1.8yrs	€151.00k	sin datos

4.2yrs

Permanencia media

59yo

Promedio de edad

Junta con experiencia: La junta directiva de 0PMJ se considera experimentada (4.2 años de antigüedad promedio).

Siemens Healthineers Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Siemens Healthineers AG Appoints Vivek Kanade as Head of Middle East and Africa

Siemens Healthineers AG, Annual General Meeting, Apr 18, 2024

Siemens Healthineers AG, Annual General Meeting, Feb 15, 2023

Recent updates

New major risk - Financial position

Full year 2024 earnings released: EPS: €1.74 (vs €1.35 in FY 2023)

Siemens Healthineers AG to Report Fiscal Year 2024 Results on Nov 26, 2024

Siemens Healthineers Offers to Buy Novartis Molecular Imaging Business

Second quarter 2024 earnings released: EPS: €0.38 (vs €0.09 in 2Q 2023)

Upcoming dividend of €0.95 per share

First quarter 2024 earnings released: EPS: €0.39 (vs €0.38 in 1Q 2023)

Siemens Healthineers AG Appoints Vivek Kanade as Head of Middle East and Africa

Siemens Healthineers AG, Annual General Meeting, Apr 18, 2024

Full year 2023 earnings released: EPS: €1.35 (vs €1.82 in FY 2022)

Siemens Healthineers AG to Report Fiscal Year 2023 Final Results on Nov 27, 2023

Siemens Healthineers AG to Report Q2, 2024 Results on May 06, 2024

Siemens Healthineers AG to Report Q1, 2024 Results on Feb 01, 2024

Third quarter 2023 earnings released: EPS: €0.40 (vs €0.32 in 3Q 2022)

Now 23% undervalued after recent price drop

Now 20% undervalued after recent price drop

Now 21% undervalued after recent price drop

Now 20% undervalued

Second quarter 2023 earnings released: EPS: €0.093 (vs €0.52 in 2Q 2022)

Upcoming dividend of €0.95 per share at 1.8% yield

First quarter 2023 earnings released: EPS: €0.38 (vs €0.41 in 1Q 2022)

Siemens Healthineers AG to Report Q1, 2023 Results on Feb 02, 2023

Siemens Healthineers, GE Healthcare Studying Potential Deals with Medtronic's Spun Off Units

Siemens Healthineers AG to Report Q2, 2023 Results on May 10, 2023

Siemens Healthineers AG, Annual General Meeting, Feb 15, 2023

Now 20% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Now 22% undervalued after recent price drop

Second quarter 2022 earnings released: EPS: €0.52 (vs €0.41 in 2Q 2021)

Upcoming dividend of €0.85 per share

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Siemens Healthineers Launches Enhanced Liver Fibrosis (ELF) Test in the U.S

Siemens Healthineers Announces FDA Emergency Use Authorization For CLINITEST® Rapid COVID-19 Antigen Self-Test

Full year 2021 earnings released: EPS €1.57 (vs €1.41 in FY 2020)

FDA Grants Marketing Authorization to Siemens Healthineers's ELF Test for NASH Prognostic Assessment

Second quarter 2021 earnings released: EPS €0.41 (vs €0.41 in 2Q 2020)

Upcoming Dividend of €0.80 Per Share

New 90-day high: €44.37

New 90-day high: €42.35

Renown Institute for Health Innovation Expands Partnership with Gilead Sciences, Inc. and Siemens Healthineers to Offer ELF- Enhanced Liver Fibrosis Testing for Nevada Nash Study Participants

New 90-day high: €39.83

Siemens Healthineers AG to Report Q1, 2021 Results on Feb 01, 2021

Revenue misses expectations

Full year 2020 earnings released: EPS €1.41

Revenue misses expectations

Full year 2020 earnings released: EPS €1.41

Siemens Healthineers and University of Iowa Health Care Team Up to Advance Care for Iowans Over the Next Decade

Siemens Healthineers and WakeMed Health & Hospitals Announce Innovative Relationship to Advance Care and Improve Outcomes

Siemens Healthineers Announces Collaboration Agreement for Assay Development with an Initial Focus on Multiple Sclerosis

Siemens Healthineers AG has completed a Follow-on Equity Offering in the amount of €2.73 billion.

New 90-day low - €39.62

New 90-day low - €40.02

Earnings released

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad